Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Glioblastoma 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Gliosarcoma 6Burkitt Lymphoma 6Astrocytoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Myeloproliferative Disorders 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Oligodendroglioma 4Medulloblastoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Carcinoma, Renal Cell 4Breast Neoplasms, Male 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3

Interventions

Carboplatin 28Paclitaxel 21Cisplatin 9Topotecan 8Docetaxel 7Taxes 6Oxaliplatin 5Gemcitabine 5Chemotherapy, Adjuvant 5Bevacizumab 5aldesleukin 4Interleukin-12 Subunit p35 4Erlotinib Hydrochloride 4Drug Therapy 4Interleukin-12 3Immunohistochemistry 3Imatinib Mesylate 3Gene Expression Profiling 3Flow Cytometry 3Filgrastim 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3trioctyl phosphine oxide 2temsirolimus 2sargramostim 2oregovomab 2ixabepilone 2irofulven 2cediranib 2carboxyamido-triazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma, Ovarian Epithelial × Vorinostat × Clear all
NCT00132067 2019-07-23

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Neoplasms, Oropharyngeal Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡